<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681473</url>
  </required_header>
  <id_info>
    <org_study_id>06-195</org_study_id>
    <nct_id>NCT00681473</nct_id>
  </id_info>
  <brief_title>Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma</brief_title>
  <official_title>Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, we are looking to study the side effects from the use of proton
      radiation in treating people with low-grade gliomas that are recommended radiation treatment.
      We expect response of the tumors to be the same with proton radiation as compared to standard
      3D conformal radiation therapy, but also expect less side effects from radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will receive radiation therapy for 6 weeks, given in daily doses, Monday
           through Friday, for a total of 30 treatments.

        -  A medical history and physical examination will be performed prior to the start of
           radiation treatment, weekly during the 6 weeks of radiation and after the finish of
           radiation performed at 3 and 6 months and then annually for 5 years.

        -  Hormonal function tests will be taken prior to the start of radiation treatment and
           after the finish of radiation treatment at 3 and 6 months, and annually for five years
           to assess the participants hormonal functions as they relate to the pituitary gland's
           function.

        -  A brain MRI will be performed prior to the start of radiation treatment and then
           performed at 3 and 6 months after radiation treatment then annually for 5 years.

        -  A neurocognitive exam will be performed prior to the start of radiation therapy, a
           limited exam 6 months after the completion of radiation therapy, and a complete exam
           annually for 5 years.

        -  Quality of Life and Emotional Well-Being Questionnaires will be done before radiation
           begins, 2 months after radiation treatment, 6 months after radiation treatment and then
           annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Late Effects &gt; 3 Months Post RT</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Progression Free Survival</measure>
    <time_frame>At 1, 3, and 5 years</time_frame>
    <description>Clinical and/or radiographic assessments Percentages were estimated by Kaplan Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival</measure>
    <time_frame>At 1, 3, and 5 years</time_frame>
    <description>Percentages were estimated by Kaplan Meier</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Low Grade Gliomas</condition>
  <arm_group>
    <arm_group_label>Proton Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiation Therapy</intervention_name>
    <description>Once daily, Monday through Friday, for 6 weeks.</description>
    <arm_group_label>Proton Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed low-grade gliomas, WHO classification II/IV or equivalent low
             grade histology, including protoplasmic, fibrillary, gemistocytic astrocytomas, and
             mixed variants such as oligoastrocytomas

          -  Must have at least one of: (1) progressive or recurrent disease as defined by imaging,
             (2) persistence or progression of debilitating neurological symptoms, or (3) at risk
             of early progression as defined by either (a) age of 40 or older or (b) MIB-1 of 3% or
             greater

          -  KPS of 70 or greater

          -  18 years of age or older

          -  Surgical and medical/chemotherapeutic interventions are per physician's discretion and
             are acceptable

          -  Must be able to speak and comprehend English

        Exclusion Criteria:

          -  Other baseline neurocognitive or emotional disorders or deficits, including but not
             limited to head injury, CVA, TIA, or other cerebral insults with residual
             neuropsychiatric deficits, psychiatric disorders, learning disabilities, HIV
             positivity or other medical conditions at high risk of causing neurocognitive decline
             or emotional instability

          -  Prior history of cranial irradiation

          -  Pregnancy at the time of radiation treatment

          -  Unable to undergo MRI scans (e.g., embedded ferromagnetic metal or pacemakers)

          -  Comorbid illness or reason to suggest a life expectancy of less than 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen A. Shih, MD, MS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <results_first_submitted>January 6, 2017</results_first_submitted>
  <results_first_submitted_qc>January 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2017</results_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Helen A. Shih, MD</investigator_full_name>
    <investigator_title>Attending Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>proton radiation therapy</keyword>
  <keyword>photon radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A large number of patients with brain tumors in the greater area are referred to one or more of the MGH multidisciplinary brain tumor specialists for evaluation and further care.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Proton Radiation Therapy</title>
          <description>Proton Radiation Therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">20 patients with WHO Grade 2 Glioma were enrolled.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">All 20 patients completed RT and tolerated treatment well.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 20 baseline participants were included in analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Proton Radiation Therapy</title>
          <description>Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" lower_limit="22" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Late Effects &gt; 3 Months Post RT</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Radiation Therapy</title>
            <description>Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Effects &gt; 3 Months Post RT</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Progression Free Survival</title>
        <description>Clinical and/or radiographic assessments Percentages were estimated by Kaplan Meier</description>
        <time_frame>At 1, 3, and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Radiation Therapy</title>
            <description>Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Progression Free Survival</title>
          <description>Clinical and/or radiographic assessments Percentages were estimated by Kaplan Meier</description>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival</title>
        <description>Percentages were estimated by Kaplan Meier</description>
        <time_frame>At 1, 3, and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Radiation Therapy</title>
            <description>Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival</title>
          <description>Percentages were estimated by Kaplan Meier</description>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years post RT</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Proton Radiation Therapy</title>
          <description>Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Visual disturbance, other than loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vision Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting, acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache, late</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting, late</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia, late</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue, acute</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache, acute</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Taste/Smell Alteration, acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paresthesia, acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia, acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Temperature Sensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stuttering, twitching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>fatigue, late</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Taste/smell alteration, late</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paresthesia, late</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure, acute</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cognitive Deficit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness, acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Motor Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weakness, cranial nerve</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weakness, peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cognitive dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Proprioceptive deficit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Seizure, late</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness, late</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alopecia, acute</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alopecia, late</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Helen A. Shih, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9627</phone>
      <email>HSHIH@Partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

